title: Re: Twardowski et al.: Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer: a California Cancer Consortium Trial (Urology 2010;76:923-926).
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Twardowski
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D014571:Urologic Neoplasms / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins